Who are CT-P13 SC (Infliximab)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TDM-based infliximab intravenous therapy, Adalimumab, etanercept, infliximab, Adalimumab with methotrexate, Infliximab-Dyyb, etanercept or adalimumab, Certolizumab Pegol (CZP).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ct-p13-sc-infliximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

CT-P13 SC (Infliximab) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CT-P13 SC (Infliximab) (CT-P13 SC (Infliximab)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-alpha inhibitor; monoclonal antibody. Area: Immunology.

phase 3 TNF-alpha inhibitor; monoclonal antibody TNF-alpha (Tumor Necrosis Factor-alpha) Immunology Biologic Live · refreshed every 30 min

Target snapshot

CT-P13 SC (Infliximab) (CT-P13 SC (Infliximab)) — Celltrion. CT-P13 SC is a subcutaneous formulation of infliximab, a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha to reduce inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CT-P13 SC (Infliximab) TARGET	CT-P13 SC (Infliximab)	Celltrion	phase 3	TNF-alpha inhibitor; monoclonal antibody	TNF-alpha (Tumor Necrosis Factor-alpha)
TDM-based infliximab intravenous therapy	TDM-based infliximab intravenous therapy	Asan Medical Center	marketed	TNF-alpha inhibitor	TNF-alpha (Tumor Necrosis Factor-alpha)
Adalimumab, etanercept, infliximab	Adalimumab, etanercept, infliximab	University of Padova	marketed	TNF-alpha inhibitor	TNF-alpha (tumor necrosis factor-alpha)
Adalimumab with methotrexate	Adalimumab with methotrexate	Pfizer	marketed	TNF-alpha inhibitor + DMARD combination	TNF-alpha; dihydrofolate reductase
Infliximab-Dyyb	Infliximab-Dyyb	Asan Medical Center	marketed	TNF-alpha inhibitor; monoclonal antibody	TNF-alpha (TNFα)
etanercept or adalimumab	etanercept or adalimumab	University of Glasgow	marketed	TNF-alpha inhibitor	TNF-alpha (tumor necrosis factor-alpha)
Certolizumab Pegol (CZP)	Certolizumab Pegol (CZP)	UCB Pharma	marketed	TNF-alpha inhibitor	TNF-alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-alpha inhibitor; monoclonal antibody class)

Asan Medical Center · 1 drug in this class
Celltrion · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CT-P13 SC (Infliximab) — Competitive Intelligence Brief. https://druglandscape.com/ci/ct-p13-sc-infliximab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab